Boehringer Ingelheim announced the grand opening of its newly expanded research and development facility in Athens, Georgia. As the largest animal health company in Georgia, this Boehringer ...

Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...

Today, the Utah Jazz announced plans to launch a first-of-its-kind program that allows fans to bring a designated Mountain Purple Jazz co-branded 40 oz Stanley(R) Quencher(R) H2.0 FlowStatetm Tumbler ...

AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...

The WHO Foundation proudly announces a five-year partnership with the number one cosmetics brand in the world, Maybelline New ...

Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...

Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...

One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding ...

As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.